Literature DB >> 31933570

Red Blood Cells: Exchange, Transfuse, or Deplete.

Georg Stussi1, Andreas Buser2,3, Andreas Holbro2,3.   

Abstract

Erythrocytapheresis, red blood cell (RBC) depletion, and RBC exchange transfusions are apheresis techniques used to rapidly lower the circulating RBC mass or to exchange the patient erythrocyte mass with donor RBC. Automated RBC exchange is performed using an apheresis device, while manual RBC exchange is based on sequential phlebotomies and isovolemic replacement. Compared to simple RBC transfusions, RBC exchange offers several advantages, e.g., a lower risk for iron accumulation and efficient control of pathological erythrocyte populations. Disadvantages are the higher costs of the procedure, the increased use of donor RBC, and the requirement of apheresis devices and trained hospital staff. The most frequent indication for RBC exchange is sickle cell disease (SCD). RBC exchange transfusions are standard treatment in SCD patients with a history of or a risk for acute stroke and are clinical options for other acute complications of SCD. The most common indication for RBC depletion is the removal of donor RBC from the bone marrow grafts in major ABO-incompatible allogeneic hematopoietic stem cell transplantation to avoid immediate hemolysis. Rare indications for RBC exchange are severe infections with intraerythrocytic pathogens such as malaria or babesiosis and severe erythrocytosis or hereditary hemochromatosis where the aim is to rapidly decrease RBC populations or the iron content. However, only few high-quality studies are available looking at the efficacy of RBC exchange in the different disease entities, and treatment is often based on low levels of evidence and should therefore be decided in close collaboration with a transfusion medicine specialist.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  ABO phenotype; Babesiosis; Erythrocytapheresis; Hematopoietic stem cell transplantation; Malaria; Red blood cell depletion; Red blood cell exchange; Sickle cell anemia; Transfusion

Year:  2019        PMID: 31933570      PMCID: PMC6944943          DOI: 10.1159/000504144

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  6 in total

1.  Erythrocytapheresis as a novel treatment option for adult patients with pyruvate kinase deficiency.

Authors:  Rawia F G Jensen; Morten H Dziegiel; Klaus Rieneck; Henrik Birgens; Andreas Glenthøj
Journal:  Haematologica       Date:  2020-04-09       Impact factor: 9.941

Review 2.  Transfusion and Cellular Therapy in Pediatric Sickle Cell Disease.

Authors:  Yan Zheng; Stella T Chou
Journal:  Clin Lab Med       Date:  2020-12-24       Impact factor: 1.935

3.  A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19.

Authors:  Stephen A Chitty; Sarah Mobbs; Brian S Rifkin; Steven W Stogner; Michael S Lewis; Jaime Betancourt; Jeffrey DellaVolpe; Fadi Abouzahr; Andrew M Wilhelm; Harold M Szerlip; Amay Parikh; Robert M Gaeta; Ian Rivera; Caroline Park; Benjamin Levi; George L Anesi; Karl C Alcover; Thomas B Arnold; Jeffrey T Howard; Kumar Sharma; Kathleen P Pratt; Ian J Stewart; Kevin K Chung
Journal:  Crit Care Explor       Date:  2022-03-25

4.  Red blood cell exchange for SARS-CoV-2: A Gemini of therapeutic opportunities.

Authors:  Sean M Hacking
Journal:  Med Hypotheses       Date:  2020-09-02       Impact factor: 1.538

Review 5.  The rare hemoglobin variant Hb Mizuho: report of a Swiss family and literature review.

Authors:  Linet Njue; Cesare Medri; Peter Keller; Miriam Diepold; Behrouz Mansouri Taleghani; Alicia Rovó
Journal:  Ann Hematol       Date:  2021-02-15       Impact factor: 3.673

6.  Transcranial Doppler sonography and the effect of haematopoietic stem cell transplantation in sickle cell disease.

Authors:  Sylvia Thurn; Katharina Kleinschmidt; Irena Kovacic; Christina Wendl; Ralf A Linker; Selim Corbacioglu; Felix Schlachetzki
Journal:  Neurol Res Pract       Date:  2022-04-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.